{"id":"NCT01768559","sponsor":"Sanofi","briefTitle":"Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients","officialTitle":"A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2013-01-15","resultsPosted":"2017-01-04","lastUpdate":"2017-01-04"},"enrollment":894,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Lixisenatide (AVE0010)","otherNames":["Lyxumia®","Device: Disposable self-injector prefilled pen (Delta 14®)"]},{"type":"DRUG","name":"Insulin glulisine QD","otherNames":["HMR1964","Device: Disposable self-injector prefilled pen (Apidra® Solostar®)"]},{"type":"DRUG","name":"Insulin glulisine TID","otherNames":["HMR1964","Device: Disposable self-injector prefilled pen (Apidra® Solostar®)"]},{"type":"DRUG","name":"Insulin Glargine (Mandatory background drug)","otherNames":["Device: Disposable self-injector prefilled pen (Lantus® Solostar®)"]},{"type":"DRUG","name":"Metformin (Background drug)","otherNames":[]}],"arms":[{"label":"Lixisenatide","type":"EXPERIMENTAL"},{"label":"Insulin Glulisine QD","type":"ACTIVE_COMPARATOR"},{"label":"Insulin Glulisine TID","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\n\\- To compare lixisenatide versus insulin glulisine in terms of glycosylated hemoglobin (HbA1c) reduction and body weight change at Week 26 in type 2 diabetic participants not adequately controlled on insulin glargine ± metformin.\n\nSecondary Objectives:\n\n\\- To compare the treatments/regimens on:\n\n* The percentage of participants reaching the target of HbA1c \\<7% or ≤6.5%,\n* Body weight,\n* Self-Monitored Glucose profiles,\n* Fasting Plasma Glucose (FPG),\n* Post-prandial plasma glucose (PPG) /glucose excursions during a standardized meal test (subset of participants),\n* Daily doses of insulins,\n* Safety and tolerability.","primaryOutcome":{"measure":"Change in HbA1c From Baseline to Week 26","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"Lixisenatide","deltaMin":-0.63,"sd":0.054},{"arm":"Insulin Glulisine QD","deltaMin":-0.58,"sd":0.054},{"arm":"Insulin Glulisine TID","deltaMin":-0.84,"sd":0.053}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":18},"locations":{"siteCount":199,"countries":["United States","Canada","Chile","Czechia","Estonia","France","Germany","Hungary","Italy","Latvia","Lithuania","Mexico","Poland","Romania","Russia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["27222510","31848983","29974618"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":298},"commonTop":["Hypoglycaemia","Blood glucose decreased","Nausea","Nasopharyngitis","Headache"]}}